advertisement
Abstract #22532 Published in IGR 11-1
Cochlin expression in anterior segment organ culture models after TGFβ2 treatment
Bhattacharya SK; Gabelt BT; Ruiz J; Picciani R; Kaufman PLInvestigative Ophthalmology and Visual Science 2009; 50: 551-559
PURPOSE: To determine the effect of transforming growth factor (TGF)-β2 treatment on intraocular pressure (IOP), outflow facility, and cochlin expression in vitro in monkey and pig organ-cultured anterior segments (MOCAS and POCAS). METHODS: MOCAS (rhesus and cynomolgus) or POCAS were infused with media containing 10 ng/mL TGFβ2 to one segment of each pair and 0.1% BSA (vehicle) to the contralateral segment for up to 14 days at a constant rate. Cochlin expression was determined by immunohistochemical study, ELISA, and Western blot analysis using chicken polyclonal antibodies against different regions of cochlin. RESULTS: TGFβ2 infusion produced elevated IOP in MOCAS (usually after 5 days), that was approximately 45% greater than baseline and compared to control segments. Outflow facility (OF) was decreased by approximately 40% compared with pretreatment baseline (n=5). In POCAS (n=7), IOP was increased (approximately 3 days) by approximately 75% compared with baseline and contralateral changes. The IOP elevation subsided thereafter. Cochlin levels increased with duration of TGFβ2 treatment in the media and in the region of the trabecular meshwork in both species. CONCLUSIONS: TGFβ2-induced IOP elevation was associated with an increase in cochlin secretion into the media and expression in the tissue of MOCAS and POCAS. Whether cochlin overexpression contributes to elevated IOP or is a consequence of other changes relevant to IOP elevation remains to be determined.
Dr. S.K. Bhattacharya, Bascom Palmer Eye Institute, University of Miami, Miami, Florida 33136, USA. sbhattacharya@med.miami.edu
Classification:
3.8 Pharmacology (Part of: 3 Laboratory methods)
3.5 Molecular biology incl. SiRNA (Part of: 3 Laboratory methods)
5.2 Primates (Part of: 5 Experimental glaucoma; animal models)
5.3 Other (Part of: 5 Experimental glaucoma; animal models)
